^
Association details:
| Biomarker: | RB1 deletion |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | pemrametostat (GSK3326595) (PRMT5 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3934 / 22 - PRMT5 is an actionable target in CDK4/6 inhibitor-resistant ER+/Rb-deficient breast cancer
Published date:
03/15/2023
Excerpt:
Finally, therapeutic inhibition of PRMT5 with pemrametostat synergized with fulvestrant (a selective ER degrader) against growth of ER+/Rb-deficient breast cancer cell line- and patient-derived xenografts in mice, suggesting this combination as a novel therapeutic strategy for ER+/Rb-deficient metastatic breast cancers.
Secondary therapy:
fulvestrant
